Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Recursion Pharmaceuticals Inc
RXRX
Healthcare
Biotechnology
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative...
loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:RXRX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(77)
•••
Humanist
X
Post by
Humanist
on Dec 12, 2024 10:01am
RXRX CANCER TREATMENT SHOWS PROMISE IN EARLY TRIALS
Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials Affan Mir Thu, December 12, 2024 at 8:55 AM EST 4 min read 1 In This Article: RXRX -3.24% We recently
...more
•••
Jonathon Brown
X
Post by
Jonathon Brown
on Dec 12, 2024 7:03am
Buzz on the Bullboards: Feeling holiday blues, or celebrating blue chip stocks?
Some shareholders have enjoyed early holiday gifts in the form of rising stock prices, while others have faced disappointments.
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 09, 2024 6:00pm
New Press Release - Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed partial response (PR) observed during monotherapy dose-escalation in a patient with...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 03, 2024 8:30am
New Press Release - Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile in...
read article.
(262)
•••
5oceans
X
Post by
5oceans
on Nov 29, 2024 2:16pm
Hey ...
This, like anyother story, will take time to fully develop and grow... just let it ride ...
(262)
•••
5oceans
X
Post by
5oceans
on Nov 27, 2024 10:09pm
rxrx ...
Thx NVDA.
(262)
•••
5oceans
X
Post by
5oceans
on Nov 27, 2024 9:44pm
Sorry ...
... back sooner than I expected. For the second time for me, please you listen to CNBC, Jim Cramer with Mad Money, AI ai ... mney to be made ...
(262)
•••
5oceans
X
Post by
5oceans
on Nov 27, 2024 4:24pm
Been following RXRX since Cramer's comment...
Hoping that they did their home work well done before the merger and paied fair price(I don't know how to properly value the merger but I liket it; bought in yesterday) that said, like any other
...more
(262)
•••
5oceans
X
Comment by
5oceans
on Nov 27, 2024 3:55pm
RE:RXRX is up 14% after hrs with good vol, i cant find any news
Yah ... well, that kind of activity IMO, is big money doing its thing.
(262)
•••
5oceans
X
Comment by
5oceans
on Nov 25, 2024 6:26pm
RE:Tax loss selling
Glad someone is selling ... this(theirs) combination of efforts has to bottom out or, it is bottoming out around here? Either way, someone is backing up the truck as the other(s) is dumping. This
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 20, 2024 7:00am
New Press Release - Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find...
read article.
(44)
•••
Keepdigging
X
Post by
Keepdigging
on Nov 18, 2024 9:51am
Tax loss selling
RXRX is selling off in tax loss season. Keep an eye on it for the bottom, accumulate. Looks like 2025 could be the year for results on several fronts.
(77)
•••
Humanist
X
Post by
Humanist
on Nov 13, 2024 11:50pm
RXRX RELEASE OPENPHENOM-S/16 IN GOOGLE CLOUDS NOV 12
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden Recursion Pharmaceuticals, Inc. Tue, November 12, 2024 at 4:54 PM EST 6 min read RXRX -3.43% Recursion
...more
(77)
•••
Humanist
X
Post by
Humanist
on Nov 13, 2024 11:45am
RXRX / Recursion & Exscientia Shareholders Approv to combine
Recursion and Exscientia Shareholders Approve the Proposed Combination GlobeNewswire · GlobeNewswire Inc. Recursion Pharmaceuticals Wed, November 13, 2024 at 9:08 AM EST 6 min read
...more
(77)
•••
Humanist
X
Post by
Humanist
on Nov 06, 2024 5:34pm
RXRX REPORT 3RD QTR 2024 EARNINGS & BUSINESS UPDATE TDY AMC
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results Recursion Pharmaceuticals Recursion Pharmaceuticals Wed, November 6, 2024 at 4:15 PM EST In This Article: RXRX +2
...more
(77)
•••
Humanist
X
Post by
Humanist
on Oct 22, 2024 11:32am
RXRX 1ST PATIENT IN PHASE 2 STUDY/POTENTIAL FIRST-IN-CLASS
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Q Precious & Battery Metals To Resume Diamond Drilling La Corne South Project, Val D'or Quebec
Do you want to stay ahead of the markets? See how DealRoom can help.
Why Dozens of Pro Athletes are Paying Attention to this Product